Ernexa Therapeutics
Cambridge
About Ernexa Therapeutics
Ernexa Therapeutics is working on cutting-edge mRNA cell engineering technologies to fix cellular malfunction and treat a variety of therapeutic purposes. We and our strategic partners are developing novel nucleic acid and cell therapies that have the potential to significantly improve the health outcomes of people with significant unmet medical needs. We are dedicated to ensuring that patients and their families have access to life-changing treatments for critical illnesses. The IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. Brooklyn ImmunoTherapeutics serves patients and customers in the State of New York.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $56.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2025)
- Ticker: nasdaq:ERNA
- Website: ernexatx.com
- Phone: (212)-582-1199
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Canonical: https://fsome.com/organization/ernexa-therapeutics-17848 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.